End-to-End Bioinformatics Solution for Next-Generation Sequencing

MSI-H incidence is approximately 15% in early-stage CRCS. This subset has demonstrated favourable outcomes in response to PD-1 blockade versus MSS CRC.
VarSome Suite is brought to you by Saphetor SA.
© 2024 Saphetor SA – All Rights Reserved.